In the treatment of NSCLC, three PD-1 mAbs have been developed by different domestic industries: camrelizumab,99,100 sintilimab,101,102 and tislelizumab,103,104 which have all been approved by the NPMA as the first-line treatment of both EGFR/ALK-negative nonsquamous and squamous NSCLC in combination with chemotherapy, regardless of PD-L1 expression. Here, ALK is linked to non-small cell lung carcinoma.